Page last updated: 2024-11-13
coumatetralyl
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
coumatetralyl: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 54678504 |
CHEMBL ID | 3184636 |
CHEBI ID | 80742 |
SCHEMBL ID | 5933927 |
SCHEMBL ID | 137261 |
MeSH ID | M0045840 |
Synonyms (67)
Synonym |
---|
AC-12689 |
racumin |
coumarin, 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)- |
einecs 227-424-0 |
bayer 25 634 |
endox |
raucumin 57 |
2h-1-benzopyran-2-one, 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthalenyl)- |
coumatetralyl [bsi:iso] |
epa pesticide chemical code 496100 |
rodentin |
ccris 6923 |
bay 25634 |
cumatetralyl [german, dutch] |
endrocide |
3-(d-tetralyl)-4-hydroxycoumarin |
4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin |
3-(alpha-tetralyl)-4-hydroxycoumarin |
3-(1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycumarin [german] |
4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)-cumarin |
bay ene 11183 b |
4-idrossi-3-(1,2,3,4-tetraidro-1-naftil)-cumarina [italian] |
coumatetralyl |
brn 1323631 |
4-hydroxy-3-(1,2,3,4-tetrahydro-1-naftyl)-cumarine [dutch] |
hsdb 1725 |
4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthalenyl)-2h-1-benzopyran-2-one |
3-(1,2,3,4-tetrahydro-1-naphtyl)-4-hydroxycoumarine [french] |
ene 11183 b |
3-(alpha-tetral)-4-oxycoumarin |
caswell no. 496a |
endrocid |
5836-29-3 |
dtxsid8041799 , |
NCGC00255682-01 |
cas-5836-29-3 |
tox21_301252 |
dtxcid6021799 |
4-idrossi-3-(1,2,3,4-tetraidro-1-naftil)-cumarina |
unii-nwk4hw86a8 |
3-(1,2,3,4-tetrahydro-1-naphtyl)-4-hydroxycoumarine |
4-hydroxy-3-(1,2,3,4-tetrahydro-1-naftyl)-cumarine |
cumatetralyl |
3-(1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycumarin |
nwk4hw86a8 , |
3-(1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin |
AKOS015903266 |
SCHEMBL5933927 |
SCHEMBL137261 |
coumatetralyl [hsdb] |
3-(.alpha.-tetralyl)-4-hydroxycoumarin |
2h-1-benzopyran-2-one, 4-hydroxy-3-(1,2,3,4-tetrahydro-1- naphthalenyl)- |
4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthalenyl)-2h-1- benzopyran-2-one |
3-(.alpha.-tetral)-4-oxycoumarin |
coumatetralyl [iso] |
CHEBI:80742 , |
3-(1-tetralyl)-4-hydroxycoumarin |
4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthalenyl)-2h-chromen-2-one # |
ULSLJYXHZDTLQK-UHFFFAOYSA-N |
coumetralyl |
3-(1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarine |
3-(.alpha.-tetralinyl)-4-hydroxycoumarin |
CHEMBL3184636 |
4-hydroxy-3-(1,2,3,4-tetrahydronaphthalen-1-yl)-2h-chromen-2-one |
coumatetralyl, pestanal(r), analytical standard |
Q415772 |
4-hydroxy-3-(1,2,3,4-tetrahydronaphthalen-1-yl)chromen-2-one |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
hydroxycoumarin | Any coumarin carrying at least one hydroxy substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (10)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 79.6407 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 48.5577 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 2.1690 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
AR protein | Homo sapiens (human) | Potency | 48.9662 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743063 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 58.4254 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 30.6379 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.6448 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 11.3910 | 0.0010 | 19.4141 | 70.9645 | AID743094; AID743140; AID743191 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 61.1306 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 61.1306 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (21)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (28.57) | 18.7374 |
1990's | 3 (14.29) | 18.2507 |
2000's | 5 (23.81) | 29.6817 |
2010's | 7 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 32.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.65) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 3 (13.04%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 20 (86.96%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |